-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Ibere Pharmaceuticals quarterly/annual Operating Income (Loss) history and growth rate from Q4 2020 to Q3 2022.
- Ibere Pharmaceuticals Operating Income (Loss) for the quarter ending September 30, 2022 was -$234K, a 26% increase year-over-year.
- Ibere Pharmaceuticals Operating Income (Loss) for the twelve months ending September 30, 2022 was -$1.04M, a 59.7% decline year-over-year.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)